Wikipedia

Concord New Energy

(Redirected from China Windpower Group)

Concord New Energy Group Limited is an investment holding company and is listed on the Hong Kong stock exchange with its Hong Kong headquarters at Admiralty, Hong Kong. The company had a management office in Beijing. The Company and its subsidiaries are engaged in engineering, procurement and construction (EPC), operation and maintenance of wind power plants, the manufacture of wind power equipment and other wind power related business. The listed company and its predecessor, had a few former names: Nam Pei Hong (Holding) Limited, Nam Pei Hong International Holdings Limited, N P H International Holdings Limited, Hong Kong Pharmaceutical Holdings Limited and most recently China Windpower Group Limited.

Concord New Energy Group
Formerly
  • Nam Pei Hong International Holdings
  • N P H International Holdings
  • Hong Kong Pharmaceutical Holdings
  • China Windpower Group
Company typelisted
SEHK: 182
IndustryPublic utility
PredecessorNam Pei Hong (Holding)
Founded
  • 1984 in Hong Kong (predecessor)
  • 1997 in Bermuda[1] and Hong Kong
  • 2007 (backdoor listing)
Headquarters
Hong Kong S.A.R., China(second registered office)
Beijing, China(management centre)
Hamilton, Bermuda(registered office)
Subsidiaries
Nam Pei Hong Sum Yung Drugs(former)
China Wind Power Holdings
Chinese name
Simplified Chinese协合新能源集团有限公司
Traditional Chinese協合新能源集團有限公司
Transcriptions
Standard Mandarin
Hanyu PinyinXiéhé xīnnéngyuán jítuán yǒuxiàn gōngsī
Yue: Cantonese
Yale Romanizationhip hahp sān nàhng yùhn jaahp tyùhn yáuh haahn gūng sī
Jyutpinghip3 hap6 san1 nang4 jyun4 zaap6 tyun4 jau5 haan6 gung1 si1
China Windpower Group Limited
Simplified Chinese中国风电集团有限公司
Traditional Chinese中國風電集團有限公司
Transcriptions
Standard Mandarin
Hanyu PinyinZhōngguó fēngdiàn jítuán yǒuxiàn gōngsī
Yue: Cantonese
Yale Romanizationjūng gwok fūng dihn jaahp tyùhn yáuh haahn gūng sī
Jyutpingzung1 gwok3 fung1 din6 zaap6 tyun4 jau5 haan6 gung1 si1
Hong Kong Pharmaceutical Holdings Limited
Simplified Chinese香港药业集团有限公司
Traditional Chinese香港药業集團有限公司
Transcriptions
Standard Mandarin
Hanyu PinyinXiānggǎng yàoyè jítuán yǒuxiàn gōngsī
Yue: Cantonese
Yale Romanizationhēung góng yeuhk yihp jaahp tyùhn yáuh haahn gūng sī
Jyutpinghoeng1 gong2 joek6 jip6 zaap6 tyun4 jau5 haan6 gung1 si1
Nam Pei Hong International Holdings Limited
Traditional Chinese南北行國際集團有限公司
Transcriptions
Nam Pei Hong (Holding) Limited
Traditional Chinese南北行（集團）有限公司
Transcriptions
Websitewww.cnegroup.com

History

edit

The company was known as Hong Kong Pharmaceutical Holdings Limited (or just Hong Kong Pharmaceutical; Chinese: 香港葯業 or 香港藥業 or just 港葯/港藥) from 2000 to 2007. It was previously known as "N P H International Holdings Limited" from 1997 to 2000,[2]: 11  as well as Nam Pei Hong International Holdings Limited in 1997.[3] From 2007 to 2015, the listed company was known as China WindPower Group Limited.

Nam Pei Hong International

edit

Nam Pei Hong International Holdings was a Bermuda-incorporated offshore company. Nam Pak Hong (Chinese: 南北行) was a kind of trading company that import and export goods from China. Bonham Strand was also nicknamed "Nam Pak Hong street" in Chinese language. However, the listed company did not headquartered in Bonham Strand, also did not own any properties on that street.[4] However, the listed company was the parent company of Nam Pei Hong Sum Yung Drugs Company Limited (南北行參茸葯材有限公司), a trading company in Chinese medicine such as dried abalone, birds' nests, dried scallops, ginseng, etc.

Before 1997, the business was incorporated and listed in Hong Kong as Nam Pei Hong (Holding) Limited (Chinese: 南北行（集團）有限公司). It was incorporated in 1984[3] and listed on 27 November 1991.[5][6] Soon after the Hong Kong incorporated holding company, Nam Pei Hong (Holding), became a subsidiary of the Bermuda-incorporated new holding company in 1997, it was renamed to Foster (Group) Limited from 1998 to 2000.[3][7]: 53  As of 31 March 2006, it was still a wholly owned subsidiary of the group.[8]: 44  However, after the listed company became an investment vehicle for a backdoor listing, the Nam Pei Hong division was sold to Johnson Ko, one of the shareholder of the listed company in 2009, for HK$34 million.[9] Nam Pei Hong (Holding) was dissolved by striking-off in 2010.[3] However, as of 2019,[3] the former subsidiaries,[9] Nam Pei Hong Sum Yung Drugs[10] and N P H Sino-Meditech Limited, were live companies.

Hong Kong Pharmaceutical

edit

It was reported that Heilongjiang Economic Development Corp. (Chinese: 黑龍江經濟開發集團公司) acquired the controlling stake of the listed company in 1996 [sic].[11] The Hong Kong stock exchange also publicly criticised the listed company and former managers for failing to disclose the sale of the company in time.[12] According to South China Morning Post, Victory Hunter Holdings, an investment vehicle owned by Yau Wai-ming (Chinese: 邱伟铭; pinyin: Qiū Wěimíng) of Heilongjiang provincial government [sic], acquired 33% stake of the listed company from International Tak Cheung Holdings [zh], the former significant owner of the listed company in July 1997.[12] According to a press release, Yau transferred the stake of Victory Hunter Holdings to Hong Tau Investment in 1999 for HK$1.[13] 2 directors of the listed company, Sun Hiu-lu [sic] (simplified Chinese: 孙晓路; traditional Chinese: 孫曉路; pinyin: Sūn Xiǎolù) and Chu Kwan [sic] (Chinese: 朱均; pinyin: Zhū Jūn), via Welcome Success Worldwide Limited, owned 51% stake of Hong Tau, however, themselves did not have "a casting vote or control of Welcome Success Worldwide".[13] The remaining 49% stake of Hong Tau were owned by Heilongjiang Economic Development[13] (which was later renamed to Heilongjiang China United Co., Ltd.; Chinese: 黑龍江中盟集團有限公司[14]: 15 ) and another government-owned company Heilongjian International Trust Investment Corporation.[13] According to the last publication before 2004 suspension, as at 30 September 2003, Hong Tau still owned a majority stake (67.2%) of the listed company[15]: 23, 26–27  It was reported that Sun acquired the aforementioned stake from Yau in 1999, also caused a price fluctuation of the shares of the listed company.[16]

The listed company was renamed to Hong Kong Pharmaceutical Holdings Limited in 2000.[16] The listed company acquired several Mainland China based businesses.[16]

However, the poor management under new owner(s), had caused the listed company in the brink of liquidation in 2004.[11]

In 2005, Johnson Ko Chun-shun [zh] (Chinese: 高振順; Jyutping: Gou1 Zan3 Seon6; Cantonese Yale: Gōu Jan Seuhn) acquired the controlling stake (85.2%) of the listed company from the liquidator.[17] The listed company also sold two Mainland-incorporated subsidiaries to the bond holders.[17] The listed company also said to be refocus on Nam Pak Hong trading business,[17] despite the division was sold to Ko in 2009. Johnson Ko was the chairman of the company from 2006 until 2009, which his position was changed to vice-chairman in June 2009.[18] After a reverse IPO in 2007, Johnson Ko was still one of the major shareholders of the company until 2015. In May 2015, he sold most of his shareholding (held via a company he owned: Gain Alpha) of Concord New Energy, which was decreased from 22.36% to 2.24% of the share capital.[19] Johnson Ko and his daughter Samantha Ko Wing-yan [zh] were resigned as directors of the company in June 2015.[20]

In December 2006, the listed company was resumed from trading after more than 2 years of suspension. The closing price was HK$0.47 per share, or a decrease of HK$1.47 in magnitude.[11]

China WindPower Group

edit

In April 2007 Hong Kong Pharmaceutical acquired China Wind Power Holdings Limited[21]: 71  as a reverse IPO.[22] The listed company also renamed to China WindPower Group Limited (upper cap "P") after the deal.[3] The listed company also owned a subsidiary that known as "China Windpower Group Limited" until 2009. China Windpower (lower cap "p") was sold to Johnson Ko, which China Windpower (lower cap "p") was the direct parent company of Nam Pei Hong Sum Yung Drugs business (see above section #Nam Pei Hong International for the details).

The company and its subsidiaries were engaged in engineering, procurement and construction (EPC), operation and maintenance of wind power plants, the manufacture of wind power equipment and other wind power related business.

In 2009, fellow listed company CLP Group acquired 50% stake of a subsidiary of China WindPower Group for HK$101.3 million. The joint venture and former subsidiary, CLP-CWP Wind Power Investment Limited, owned wind farms in Fuxin, Liaoning Province, China.[23]

Concord New Energy

edit

In 2015, the listed company was renamed to Concord New Energy Group Limited.[24] According to the press release, since the company had acquired solar farm in 2011, the company's newly installed power generating capacity had been mainly from solar power since 2014, thus renaming the company.[25]

In November 2017, the company suspended the issuance of its bond. The public offering of the bond was resumed in January 2018.[26] In 2017, Fitch Ratings assigned a "BB−" rating to the company.[27]

In 2018, Concord New Energy was part of the consortium to provide venture funding to Malta Inc., a spin off of Alphabet Inc.[28]

References

edit
  1. ^ "Review of Companies Register- C Public Companies". Bermuda Registrar of Companies. Archived from the original on 29 October 2017. Retrieved 8 April 2019. 23515 CONCORD NEW ENERGY GROUP LIMITED 6/27/1997
  2. ^ "Report of the Directors" (PDF). Annual Report 2000/2001 (Report). Hong Kong Pharmaceutical Holdings. 7 August 2001. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  3. ^ a b c d e f Hong Kong Company Registry database
  4. ^ Annual Report 2000/2001 (Report). Hong Kong Pharmaceutical Holdings. 7 August 2001. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  5. ^ "CONCORD NEW ENERGY GROUP LTD. (182)". Hong Kong Exchanges and Clearing. Retrieved 8 April 2019.
  6. ^ "Coverpage - MMIS" 每股作價七角七仙　南北行發售新股上市　集資開設新店及廠房. Ta Kung Pao (in Chinese (Hong Kong)). Hong Kong. 12 November 1991. p. 24 – via MMIS, Hong Kong Public Libraries.
  7. ^ "Notes to Financial Statements" (PDF). Annual Report 2000/2001 (Report). Hong Kong Pharmaceutical Holdings. 7 August 2001. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  8. ^ "Notes to Financial Statements" (PDF). 2006 Annual Report (Report). Hong Kong Pharmaceutical Holdings. 18 August 2006. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  9. ^ a b "MAJOR AND CONNECTED TRANSACTION DISPOSAL OF NPH GROUP AND RESUMPTION OF TRADING" (PDF) (Press release). China WindPower Group. 6 March 2009. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  10. ^ 南北行 – 主頁 [Nam Pei Hong - main page] (in Chinese (Hong Kong)). Hong Kong: 南北行參茸葯材 [Nam Pei Hong Sum Yung Drugs]. Retrieved 8 April 2019.
  11. ^ a b c 港葯復牌狂瀉七成半. 太陽報 [The Sun ] (in Chinese (Hong Kong)). Hong Kong: Oriental Press Group. 8 December 2006. Retrieved 8 April 2019.
  12. ^ a b Yiu, Enoch (18 December 1998). "Exchange raps Nam Pei Hong over sale". South China Morning Post. Hong Kong. Retrieved 8 April 2019.
  13. ^ a b c d "Announcement" (Press release). N P H International Holdings. 31 May 1999. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  14. ^ "Report of the Directors" (PDF). Annual Report 2002/2003 (Report). Hong Kong Pharmaceutical Holdings. 22 December 2003. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  15. ^ Interim Report 2003/2004 (PDF) (Report). Hong Kong Pharmaceutical Holdings. 19 January 2004. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing.
  16. ^ a b c 何晓晴 (June 2003). 四通高科幕后玩家揭秘. 财经界 (in Chinese (China)). No. 213.
  17. ^ a b c 高振順8019萬入主港藥 [Ko Chun-shun acquires Hong Kong Pharmaceutical for (HK$)80,19 million]. Apple Daily (in Chinese (Hong Kong)). Hong Kong: Next Digital. 28 September 2005. Retrieved 8 April 2019.
  18. ^ 李華華 (12 June 2009). 中國風電正副主席玩執位. 中環在線 column. Apple Daily (in Chinese (Hong Kong)). Hong Kong: Next Digital. Retrieved 8 April 2019.
  19. ^ 協合新能源(00182.HK)遭副主席高振順配股減持18億股. aastocks.com (in Chinese (Hong Kong)). 15 May 2015. Retrieved 8 April 2019 – via Yahoo!HK News.
  20. ^ 2015 Annual Report (PDF) (Report). Concord New Energy. 26 April 2016. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing website.
  21. ^ "Notes to Financial Statements". 2007 Annual Report (PDF) (Report). Hong Kong Pharmaceutical Holdings. 6 July 2007. Retrieved 8 April 2019 – via Hong Kong Exchanges and Clearing website.
  22. ^ 龔成 (3 December 2015). 協合新能源何時可買？. 經濟一周 [Economic Digest] (column) (in Chinese (Hong Kong)). Hong Kong: 新傳媒集團 [New Media Group]. Retrieved 8 April 2019.
  23. ^ "CLP and China WindPower Group Co-invest in Wind Projects in China" (PDF) (Press release). Hong Kong: CLP Group. 17 March 2009. Retrieved 8 April 2019.
  24. ^ 中國風電擬改名為協合新能源. online instant news. Hong Kong Economic Journal (in Chinese (Hong Kong)). 8 January 2015. Retrieved 7 April 2019.
  25. ^ 中國風電(182)擬更名為「協合新能源集團有限公司」 [China WindPower (182) was proposed to rename to Concord New Energy Group Limited]. Quam Net (in Chinese (Hong Kong)). Hong Kong. 9 January 2015. Retrieved 8 April 2019.[permanent dead link]
  26. ^ Manju Dalal (17 January 2018). "Asian Bond Issuance Is on the Rise. For Some Companies, So Are Borrowing Costs". The Wall Street Journal. New York city. Retrieved 8 April 2019.
  27. ^ "Fitch Assigns First-Time 'BB-' Rating to Concord New Energy; Rates USD Notes 'BB-(EXP)" (Press release). Hong Kong; Shanghai: Fitch Ratings. 7 November 2017. Retrieved 8 April 2019 – via Reuters.com.
  28. ^ Chediak, Mark; Bergen, Mark (19 December 2018). "Gates Among Billionaires Backing Alphabet Energy Spinoff". Bloomberg. Retrieved 7 April 2019.
edit
Retrieved from "https://en.wikipedia.org/w/index.php?title=Concord_New_Energy&oldid=1253632378#China_WindPower_Group"